Morgans believes there is value (unrecognised by the market) in Volpara Health Technologies’ data set (51m images) that could be worth up to $100m. The broker adopts a changed valuation method and raises its target price to $1.94 from $1.87. Add retained.
Via a recent newsletter, the analyst notes management declared the 3Q22 has been strong and will beat the previous best 3Q in terms of new annual recurring revenue (ARR).
Sector: Health Care Equipment & Services.
Target price is $1.94.Current Price is $0.91. Difference: $1.03 – (brackets indicate current price is over target). If VHT meets the Morgans target it will return approximately 100% (excluding dividends, fees and charges – negative figures indicate an expected loss).
